TY - JOUR
T1 - Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial
T2 - A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
AU - Chisholm, Julia
AU - Mandeville, Henry
AU - Adams, Madeleine
AU - Minard-Collin, Veronique
AU - Rogers, Timothy
AU - Kelsey, Anna
AU - Shipley, Janet
AU - van Rijn, Rick R
AU - de Vries, Isabelle
AU - van Ewijk, Roelof
AU - de Keizer, Bart
AU - Gatz, Susanne A
AU - Casanova, Michela
AU - Hjalgrim, Lisa Lyngsie
AU - Firth, Charlotte
AU - Wheatley, Keith
AU - Kearns, Pamela
AU - Liu, Wenyu
AU - Kirkham, Amanda
AU - Rees, Helen
AU - Bisogno, Gianni
AU - Wasti, Ajla
AU - Wakeling, Sara
AU - Heenen, Delphine
AU - Tweddle, Deborah A
AU - Merks, Johannes H M
AU - Jenney, Meriel
PY - 2024/2/29
Y1 - 2024/2/29
N2 - The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.
AB - The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.
U2 - 10.3390/cancers16050998
DO - 10.3390/cancers16050998
M3 - Article
C2 - 38473359
SN - 2072-6694
VL - 16
JO - Cancers
JF - Cancers
IS - 5
ER -